Noida, India

Saurabh Srivastava

USPTO Granted Patents = 6 

Average Co-Inventor Count = 5.6

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2020-2023

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovator Spotlight: Saurabh Srivastava

Introduction: Saurabh Srivastava, an accomplished inventor based in Noida, India, has made significant strides in the pharmaceutical field. With six patents to his name, he has demonstrated a commitment to innovation and the development of effective medical solutions.

Latest Patents: Among his notable inventions are two recent patents focused on the oral administration of eslicarbazepine. The first, titled "Eslicarbazepine Suspension," involves liquid pharmaceutical compositions that are ready for use as suspensions or as powders for reconstitution. These compositions aim to address the challenges faced by patients who struggle with swallowing tablets, offering a more convenient and practical option for medication administration. The second patent, "Modified Release Suspension of Eslicarbazepine," focuses on an extended-release formulation that includes eslicarbazepine in a pharmaceutically acceptable carrier. This innovation improves upon existing immediate-release forms by offering desired technical attributes and extended therapeutic effects.

Career Highlights: Saurabh Srivastava is currently employed at Jubilant Generics Limited, where he contributes to the development of groundbreaking pharmaceutical solutions. His expertise in crafting effective formulations has made him a valuable team member in the research and development sector.

Collaborations: Throughout his career, Saurabh has collaborated with talented coworkers such as Dinesh Kumar and Kamal Surendrakumar Mehta. Working alongside these professionals, he has leveraged their collective knowledge to push the boundaries of innovation in pharmaceutical formulations.

Conclusion: Saurabh Srivastava is a remarkable inventor whose contributions to the pharmaceutical industry have the potential to enhance patient care significantly. His focus on liquid formulations of eslicarbazepine addresses a critical need in medication delivery, showcasing the importance of innovation in improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…